
NYSE:BAC
This summary was created by AI, based on 23 opinions in the last 12 months.
Bank of America (BAC) continues to position itself favorably within the banking sector, driven by deregulation and solid performance indicators. Experts have pointed out its impressive profit growth of 17% in the last quarter, indicating strong operational efficiency and guidance for continued upside potential. The bank benefits from improving net interest margins, a strengthening economy, and a favorable yield curve, despite facing some concerns regarding private debt and market fluctuations. With analysts projecting valuations that suggest potential upside, it remains a recommended buy on dips, particularly due to its diverse business model and robust consumer banking performance.
(A Top Pick March 21/17. Up 40.77%) Continues to be one of his top 10 holdings. The story continues to play out. Tax changes help. Rising interest rates help. The growing US economy helps. Cost cutting helps. This is one that can continue to do very well. It's only trading at about 1.4X BV. It’s traded as high as 3X BV in the past.
(For a 5-year hold?) Pretty well everybody in the sector has done a lot to take costs down, and make investments into digital enterprise. You have the combination of a rising rate environment that will be helpful. Credit quality across the group remains really strong. All this bodes well for the banks. She prefers Citigroup (C-N).
Wouldn't be a buyer at this level. He paid $6+, and it has done very, very well. There is still upside, partially because US interest rates are going up and partially because corporations will do better in the short run with better regulations. His initial sell target is $38+. He is happy to hold this.
Earnings are coming out on Thursday of next week. It closed at $30.66, and his model price is $32.16. He can see this racing up to $32.48. Thinks there is going to be a major dividend increase. He would be very disappointed if they don't at least double their dividend. Next year they are going to earn $2.35.
Own 2 or 3 US banks or an ETF? The ETF will do well, but Bank of America (BAC-N) is entering a sweet spot in the cycle. There are things they are doing in cutting costs. It has the most exposure to small businesses and US consumer. They’re entering a point where they can buy back a lot of stock and increase the dividend. He would choose this over an ETF.
This has participated well in the pro-growth theme and should continue to participate. The big money centred banks should get investor preference. Because they have a universal banking model, they are going to capture lots of business. You could also look at J.P. Morgan (JPM-N) or SPDR Financial ETF (XLF-N). (Analysts' price target is $31.25.)
Has liked this for a long time. It’s trading at about 13X next year's earnings. Trading at 1.2X Book, but he can see it eventually trading at 2X Book. There is a very simple story in the US banking industry. You are going to see profitability and earnings growth for a couple of reasons. 1.) The global economy is doing better and 2) credit quality will remain fairly good over the next while. Interest rates, if they go up, will help these areas. Banks are in a 5-10 year cost-saving binge, using technology more aggressively. If they can break through $30, it will go much higher. Dividend yield of 1.6%. (Analysts' price target is $30.)
This probably has the greatest leverage to a rise in interest rates. If you anticipate that the Fed is going to raise interest rates another three quarters of a point in 2018, chances are you are going to get a decent return of this bank. Also, with deregulation coming, he imagines you are going to see much bigger dividend increases.
Recommended the stock for a long time. Simple story: all the bad stuff is done, massively capitalized, continue reducing costs. Momentum on earnings. They are internationally but they are 10% of the deposits in the US. Great credit card business. 6% owned by Warren Buffet. Everything is there to be a great institution. Real opportunity to see higher prices through organic growth. (Analysts' price target is $34.43)